NasdaqCM - Delayed Quote USD

Inovio Pharmaceuticals, Inc. (INO)

10.57 +0.44 (+4.40%)
At close: April 26 at 4:00 PM EDT
10.77 +0.20 (+1.89%)
After hours: April 26 at 4:53 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
832.01
832.01
10,262.27
1,774.76
7,411.22
Operating Expense
134,258.67
134,258.67
277,835.79
302,992.68
131,493.26
Operating Income
-133,426.66
-133,426.66
-267,573.52
-301,217.92
-124,082.04
Net Non Operating Interest Income Expense
6,910.50
6,910.50
3,528.08
1,426.63
-5,390.60
Other Income Expense
-8,601.20
-8,601.20
-13,607.41
-3,433.04
-33,417.66
Pretax Income
-135,117.35
-135,117.35
-277,652.85
-303,224.32
-162,890.30
Earnings from Equity Interest Net of Tax
--
--
-2,165.21
-434.39
-4,584.61
Net Income Common Stockholders
-135,117.35
-135,117.35
-279,818.07
-303,658.71
-166,411.16
Diluted NI Available to Com Stockholders
-135,117.35
-135,117.35
-279,818.07
-303,658.71
-166,411.16
Basic EPS
-6.09
-6.09
-14.07
-17.45
-12.84
Diluted EPS
-6.09
-6.09
-14.07
-17.45
-12.84
Basic Average Shares
22,173.66
22,173.66
19,885.18
17,402.48
12,927.24
Diluted Average Shares
22,173.66
22,173.66
19,885.18
17,402.48
12,927.24
Total Operating Income as Reported
-143,940.03
-143,940.03
-267,573.52
-301,217.92
-124,082.04
Total Expenses
134,258.67
134,258.67
277,835.79
302,992.68
131,493.26
Net Income from Continuing & Discontinued Operation
-135,117.35
-135,117.35
-279,818.07
-303,658.71
-166,411.16
Normalized Income
-130,454.61
-130,454.61
-271,971.89
-300,435.87
-97,141.74
Interest Income
8,133.29
8,133.29
4,782.03
3,363.08
3,311.85
Interest Expense
1,222.79
1,222.79
1,253.95
1,936.45
8,702.45
Net Interest Income
6,910.50
6,910.50
3,528.08
1,426.63
-5,390.60
EBIT
-133,894.56
-133,894.56
-276,398.90
-301,287.88
-154,187.85
EBITDA
-130,391.03
-130,391.03
-270,902.87
-296,557.10
-149,560.06
Reconciled Depreciation
3,503.54
3,503.54
5,496.03
4,730.78
4,627.79
Net Income from Continuing Operation Net Minority Interest
-135,117.35
-135,117.35
-279,818.07
-303,658.71
-166,411.16
Total Unusual Items Excluding Goodwill
-4,662.75
-4,662.75
-7,846.17
-3,222.84
-69,269.42
Total Unusual Items
-4,662.75
-4,662.75
-7,846.17
-3,222.84
-69,269.42
Normalized EBITDA
-125,728.28
-125,728.28
-263,056.70
-293,334.26
-80,290.65
12/31/2020 - 12/8/1998

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VXRT Vaxart, Inc.
0.7097
+7.79%
 
NVAX Novavax, Inc.
4.0900
+3.54%
 
IBIO iBio, Inc.
1.7600
+2.33%
 
SRNE Sorrento Therapeutics, Inc.
0.0137
-31.50%
 
OCGN Ocugen, Inc.
1.2800
+8.47%
 
MRNA Moderna, Inc.
107.97
+1.69%
 
AGEN Agenus Inc.
11.69
+40.84%
 
ALT Altimmune, Inc.
7.26
+0.83%
 
BNTX BioNTech SE
87.21
+0.58%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%